HomeCompareAPLT vs EPRT

APLT vs EPRT: Dividend Comparison 2026

APLT yields 1941.75% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLT wins by $7549549081.27M in total portfolio value
10 years
APLT
APLT
● Live price
1941.75%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7549549081.34M
Annual income
$6,855,073,294,458,854.00
Full APLT calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — APLT vs EPRT

📍 APLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APLT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLT
Annual income on $10K today (after 15% tax)
$165,048.54/yr
After 10yr DRIP, annual income (after tax)
$5,826,812,300,290,026.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, APLT beats the other by $5,826,812,300,279,111.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLT + EPRT for your $10,000?

APLT: 50%EPRT: 50%
100% EPRT50/50100% APLT
Portfolio after 10yr
$3774774540.70M
Annual income
$3,427,536,647,235,847.50/yr
Blended yield
90.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

APLT
Analyst Ratings
5
Buy
5
Hold
1
Sell
Consensus: Buy
Price Target
$0.25
+142.7% upside vs current
Range: $0.25 — $0.25
Altman Z
-35.3
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLT buys
0
EPRT buys
0
No recent congressional trades found for APLT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLTEPRT
Forward yield1941.75%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$7549549081.34M$63.4K
Annual income after 10y$6,855,073,294,458,854.00$12,840.73
Total dividends collected$7500143229.39M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$0.25$35.50

Year-by-year: APLT vs EPRT ($10,000, DRIP)

YearAPLT PortfolioAPLT Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$204,875$194,174.76$11,205$505.18+$193.7KAPLT
2$3,937,114$3,717,897.78$12,672$682.46+$3.92MAPLT
3$70,986,064$66,773,352.36$14,490$930.48+$70.97MAPLT
4$1,201,115,737$1,125,160,648.71$16,786$1,282.69+$1201.10MAPLT
5$19,077,920,928$17,792,727,089.23$19,753$1,791.56+$19077.90MAPLT
6$284,535,588,112$264,122,212,719.20$23,677$2,541.64+$284535.56MAPLT
7$3,985,969,128,556$3,681,516,049,275.53$29,008$3,672.99+$3985969.10MAPLT
8$52,464,234,462,079$48,199,247,494,524.41$36,463$5,425.08+$52464234.43MAPLT
9$649,042,791,475,683$592,906,060,601,258.60$47,238$8,221.57+$649042791.43MAPLT
10$7,549,549,081,337,835$6,855,073,294,458,854.00$63,385$12,840.73+$7549549081.27MAPLT

APLT vs EPRT: Complete Analysis 2026

APLTStock

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Full APLT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this APLT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLT vs SCHDAPLT vs JEPIAPLT vs OAPLT vs KOAPLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.